ANDAs By The Numbers: Metrics Look Good – But Review Processes Need Attention Too

US FDA is approving generics at record pace, providing important statistics to support efforts by Commissioner Gottlieb to position the agency as part of the solution to concerns about high drug prices; new guidance for industry and FDA reviewers, however, suggests there is still a need for more rigor in preparing and assessing submissions.